Desmoplastic fibroma of bone — a rare, locally aggressive, intraosseous fibrous tumor with histologic features identical to the soft tissue desmoid tumor (deep fibromatosis), representing the intraosseous counterpart of desmoid-type fibromatosis and accounting for fewer than 0.1% of primary bone tumors, first described by Jaffe in 1958 and subsequently delineated as a distinct clinicopathologic entity; presenting most commonly in the second and third decades of life (with a mean age of approximately 17–25 years across published series, though cases are reported from infancy to the seventh decade), with no clear sex predilection; most frequently affecting the mandible (approximately 20–25% of reported cases, the most common single site), followed by the metaphysis or diaphysis of long bones (femur, tibia, humerus, and radius — accounting together for approximately 50–60% of cases), the pelvis (approximately 10–15%), and the spine (approximately 5–10%), with an imaging appearance of a well-defined or poorly defined lytic, intraosseous lesion — often with a "soap-bubble" or trabeculated pattern of bone destruction, cortical thinning, endosteal scalloping, and variable cortical breakthrough — that frequently mimics the aggressive appearance of low-grade central osteosarcoma, fibrosarcoma of bone, chondromyxoid fibroma, giant cell tumor of bone, and aneurysmal bone cyst, creating a critical diagnostic challenge that requires surgical biopsy for definitive pathologic characterization; histologically, desmoplastic fibroma of bone demonstrates hypocellular to moderately cellular spindle cell proliferation embedded in abundant dense collagenous stroma arranged in long sweeping fascicles (the "desmoid pattern"), with uniform spindled fibroblastic cells exhibiting bland, elongated nuclei without significant nuclear atypia, minimal to no mitotic activity, and no necrosis, closely mirroring the histomorphology of soft tissue desmoid tumor; immunohistochemistry demonstrates vimentin positivity, variable SMA positivity in a subset of cases, and — critically for diagnosis — nuclear beta-catenin positivity (present in approximately 60–80% of cases) reflecting CTNNB1 mutations (most frequently at exon 3 codons 41 and 45) or, less commonly, APC germline mutations in the context of Gardner syndrome (familial adenomatous polyposis-associated desmoid disease); treatment of desmoplastic fibroma of bone is primarily surgical — wide local excision with negative margins is the standard of care and provides the best local recurrence control (local recurrence rates of 15–50% reported following marginal or intralesional resection vs. lower rates with wide resection) — with radiation or systemic therapy (tyrosine kinase inhibitors, gamma-secretase inhibitors, NSAID/antiestrogen combinations) considered for unresectable or recurrent cases; its locally aggressive behavior without metastatic potential creates a management paradigm focused on achieving surgical control while minimizing morbidity, particularly in the mandible (where resection impacts speech, mastication, and facial aesthetics) and in long bones (where resection may require complex reconstruction).
Desmoplastic fibroma of bone technology platforms — supporting multidisciplinary bone tumor programs coordinating the multimodal imaging workup (plain radiographs for lesion characterization and cortical integrity assessment; MRI for soft tissue extension, medullary extent, and neurovascular proximity; CT for cortical detail, matrix characterization, and surgical planning), pathology laboratories performing the histomorphologic diagnosis with beta-catenin IHC and CTNNB1 molecular testing that confirms the intraosseous desmoid-type fibromatosis diagnosis, surgical oncology services planning wide resection and reconstruction (including mandibular reconstruction with fibular free flap, long-bone reconstruction with cortical allografts or prostheses, or pelvic reconstruction following acetabular resection), radiation oncology services managing unresectable or recurrent cases, and medical oncology services coordinating systemic therapy for aggressive or recurrent disease — must maintain the availability and performance standards demanded by the locally aggressive behavior, the complex surgical reconstruction requirements, and the diagnostic precision imperative in a rare bone tumor that frequently mimics aggressive malignancies on imaging. This guide explains why desmoplastic fibroma of bone tech platforms need dedicated monitoring, what components to monitor, and how to build a monitoring strategy matched to the clinical and surgical complexity of this rare intraosseous fibrous tumor.
Why Desmoplastic Fibroma of Bone Tech Platforms Require Specialized Monitoring Attention
Desmoplastic fibroma of bone management is shaped by several defining clinical challenges: the diagnostic imaging mimicry that creates urgency for pathologic confirmation — the lytic, locally aggressive appearance overlaps with low-grade central osteosarcoma, fibrosarcoma of bone, and giant cell tumor of bone, making biopsy and histopathologic diagnosis with beta-catenin IHC and CTNNB1 sequencing essential to avoid both under-treatment (missing an osteosarcoma) and over-treatment (applying chemotherapy or radiation to a non-metastasizing locally aggressive fibrous tumor); the surgical complexity of achieving wide negative margins in anatomically complex sites — mandibular resection with free flap reconstruction, acetabular resection with hemipelvic endoprosthesis, or diaphyseal long-bone resection with cortical allograft or intercalary prosthesis — requiring reliable access to orthopedic/oral-maxillofacial surgery planning systems, preoperative imaging, and reconstructive surgery coordination; the Gardner syndrome exclusion imperative for CTNNB1 APC-pathway cases where germline APC mutation testing determines whether colorectal screening and cascade family testing are required; and the local recurrence monitoring requirement that spans years given recurrence rates of 15–50% after marginal resection.
Imaging platforms must characterize intraosseous extent, cortical integrity, and soft tissue involvement for biopsy planning and surgical margin planning. MRI delineates the medullary and soft tissue extent; CT characterizes cortical detail and matrix; plain films document lesion morphology. Imaging platform failures delay the workup that establishes biopsy approach and surgical margin targets. Monitor imaging platforms at 1-minute intervals during clinical hours.
Pathology platforms must perform the critical beta-catenin IHC and CTNNB1 molecular testing that confirms the intraosseous desmoid diagnosis and excludes malignant fibrous tumors. Nuclear beta-catenin positivity by IHC, confirmed by CTNNB1 exon 3 sequencing when IHC is equivocal, is the molecular cornerstone distinguishing desmoplastic fibroma from low-grade fibrosarcoma and osteosarcoma. Monitor pathology platforms at 1-minute intervals during laboratory hours.
Surgical planning platforms coordinate complex resection and reconstruction that may involve multiple surgical subspecialties. Mandibular resection with fibular free flap, hemipelvic resection with endoprosthesis, or intercalary long-bone reconstruction requires reliable preoperative planning system access. Monitor surgical platforms at 1-minute intervals during clinical hours.
Surveillance platforms must document recurrence over a multi-year follow-up horizon. Post-resection MRI surveillance for local recurrence — the primary oncologic event requiring management — must be reliably accessible over a 5–10 year follow-up window.
What to Monitor on a Desmoplastic Fibroma of Bone Tech Platform
Imaging — Multimodal Characterization and Surgical Margin Planning
Monitor plain radiograph records (initial lesion characterization — lytic geographic or permeative bone destruction; trabeculated "soap-bubble" matrix; cortical thinning and endosteal scalloping; cortical breakthrough and periosteal reaction; lesion epicenter and zone of transition for aggressiveness grading; lesion size measurement), MRI records (medullary intraosseous extent — critical for surgical margin planning and determining the bone resection level; soft tissue extension — characterizing whether cortical breakthrough has resulted in a soft tissue mass and its relationship to adjacent neurovascular structures; T1 low-signal and T2 intermediate-to-high-signal fibrous tissue characterization; gadolinium enhancement pattern; mandibular canal and inferior alveolar nerve proximity in mandibular cases; neurovascular bundle proximity in long-bone and pelvic cases), CT records (cortical detail — precisely documenting cortical integrity, breakthrough location and extent, periosteal reaction morphology; matrix mineralization to exclude osteoid or chondroid matrix; CT-guided biopsy planning for pelvic and spinal cases; virtual surgical planning integration for mandibular cases), bone scan records (skeletal survey for multifocal disease in Gardner syndrome-associated cases), and preoperative CT angiography records (for cases requiring free flap reconstruction — fibular flap vascular anatomy for mandibular reconstruction, or pedicle vessel mapping for pelvic cases) at 1-minute intervals during clinical hours. Alert immediately — MRI platform failures during the preoperative assessment of a femoral desmoplastic fibroma of bone delay the medullary extent measurement that determines the proximal and distal bone resection levels and the safe margin distance from the surgical cut to the tumor edge — information on which the surgeon and prosthetics team depend to design the intercalary reconstruction.
Diagnostic Pathology — Histomorphology and CTNNB1 Molecular Confirmation
Monitor CT-guided or open biopsy planning and procedural records (biopsy site selection to avoid contamination of the future resection field; image-guided core biopsy planning; open incisional biopsy surgical planning ensuring biopsy incision falls within the planned resection field), light microscopy records (hypocellular to moderately cellular fibroblastic spindle cell proliferation; abundant dense collagen; sweeping fascicles; bland nuclei without significant atypia or pleomorphism; minimal mitotic activity; absence of osteoid production excluding low-grade osteosarcoma; absence of herringbone pattern and high-grade features of fibrosarcoma; absence of necrosis; absence of giant cells excluding giant cell tumor of bone), immunohistochemistry records (nuclear beta-catenin positivity — the key diagnostic marker; vimentin positivity; SMA variable; S100 negativity; desmin negativity; negative osteocalcin and osteocalcin excluding osteosarcoma), CTNNB1 mutation analysis records (Sanger sequencing of exon 3 at codons 41 and 45 for the T41A and S45F/S45P hotspot mutations — molecular confirmation of the desmoid-type fibromatosis diagnosis when IHC is equivocal or negative), APC germline mutation testing records (for cases where Gardner syndrome / familial adenomatous polyposis is suspected based on family history, multiple colonic polyps, or concomitant colorectal findings — APC testing determines colorectal surveillance requirements and cascade family testing), and final pathology report and multidisciplinary bone tumor board communication records at 1-minute intervals during laboratory hours. Alert immediately — pathology platform failures during CTNNB1 sequencing on bone biopsy from a 22-year-old with an aggressive lytic femoral lesion delay the molecular confirmation that distinguishes intraosseous desmoid-type fibromatosis (treatable with wide resection alone) from low-grade fibrosarcoma (requiring resection with consideration of adjuvant therapy), with direct implications for the surgical and oncologic treatment decision at the bone tumor board.
Surgical Oncology — Wide Resection and Reconstruction
Monitor preoperative virtual surgical planning records (3D-printed anatomical models for mandibular resection planning; virtual osteotomy planning software records; fibular flap harvest planning; plate bending templates; occlusal planning documentation), operative records (resection margin documentation — intraoperative specimen orientation and margin inking; frozen section records for margin assessment when feasible; neurovascular preservation documentation; reconstruction implant selection and fixation records; free flap harvest and anastomosis records for mandibular cases; intercalary prosthesis or allograft placement for long-bone cases), postoperative complication records (surgical site infection; free flap vascular compromise requiring urgent return to operating room; plate or prosthesis failure), and post-resection specimen pathology records (final margin status — the key determinant of local recurrence risk; final tumor dimensions; confirming no osteosarcoma or fibrosarcoma component missed on preoperative biopsy) at 1-minute intervals during clinical and perioperative hours. Alert immediately — surgical platform failures during virtual surgical planning for mandibular desmoplastic fibroma resection disrupt access to the 3D reconstruction planning models and fibular flap harvest templates that the orthognathic surgeon requires to plan the mandibulectomy osteotomy levels and the reconstructive plate design for the free fibula flap that will restore mandibular continuity, mastication, and facial contour.
Radiation and Medical Oncology — Unresectable and Recurrent Disease
Monitor radiation treatment planning records (simulation CT, contouring records, dose-volume histogram records for unresectable pelvic or spinal desmoplastic fibroma requiring definitive radiation; external beam radiation to 50–56 Gy targeting the primary or recurrent tumor), medical oncology systemic therapy records (NSAID therapy (sulindac or COX-2 inhibitors) and antiestrogen therapy (tamoxifen or toremifene) — the most established systemic approaches for unresectable or recurrent desmoid-type fibromatosis; tyrosine kinase inhibitors (imatinib, sorafenib) for refractory cases; gamma-secretase inhibitors (nirogacestat) for CTNNB1-mutant progressive desmoid disease — the most recent targeted approach with clinical evidence in progressive desmoid fibromatosis), and systemic therapy toxicity monitoring records (complete blood count, liver function tests, cardiac monitoring for imatinib, bowel monitoring for gamma-secretase inhibitors) at 1-minute intervals during treatment sessions. Alert immediately — medical oncology platform failures during nirogacestat or sorafenib administration for refractory unresectable desmoplastic fibroma of bone disrupt the prescribing and toxicity monitoring workflow for targeted therapy in a locally aggressive tumor causing skeletal destruction, pathologic fracture risk, and significant functional impairment.
Recurrence Surveillance — Post-Resection MRI Monitoring
Monitor post-resection MRI surveillance records (serial MRI at defined post-resection intervals — typically 3–6 months in the first 2 years, annually thereafter — documenting the operative bed, resection margin zones, and adjacent soft tissue for evidence of local recurrence; surveillance imaging site and protocol documentation; radiologic interpretation records confirming absence of or identifying recurrent T2-hyperintense fibrous tissue at the margin zone), and recurrence clinical documentation records (clinical examination findings correlating with imaging at each surveillance visit) during business hours. Alert on sustained failures — post-resection surveillance platform outages create documentation gaps in the longitudinal imaging record that is the primary mechanism for early local recurrence detection in desmoplastic fibroma of bone, where re-resection of early recurrence is more likely to achieve negative margins and definitive local control than treatment of bulky recurrent disease.
Gardner Syndrome Coordination — Colorectal and Family Cascade Management
Monitor gastroenterology colonoscopy coordination records (colorectal adenoma surveillance; FAP syndrome surveillance endoscopy scheduling; colonic polyposis documentation for APC-associated cases), hereditary cancer genetics records (APC germline mutation result documentation; cascade family testing results; colorectal cancer risk counseling records; ophthalmologic examination records for congenital hypertrophy of the retinal pigment epithelium — a Gardner syndrome marker), and family communication records (explaining APC mutation implications for colorectal cancer risk and prophylactic colectomy considerations in FAP-associated desmoplastic fibroma of bone) during business hours. Alert on sustained failures — genetics and gastroenterology platform failures in an APC-mutant desmoplastic fibroma of bone patient delay colorectal surveillance coordination that determines when prophylactic colectomy should be considered in a patient with FAP whose colorectal cancer risk is unrelated to, but identified in the evaluation of, their bone tumor.
Authentication and Clinical Identity
Monitor authentication at 1-minute intervals, 24/7. Desmoplastic fibroma of bone programs coordinate across orthopedic oncology or oral and maxillofacial surgery, musculoskeletal radiology (MRI, CT, plain radiography), molecular pathology, radiation oncology, medical oncology, plastic surgery (for free flap reconstruction), hereditary cancer genetics, and gastroenterology (for Gardner syndrome cases) — authentication failures block the full multidisciplinary team required for surgical planning, molecular confirmation, systemic therapy, recurrence surveillance, and familial cascade management.
SSL Certificates
Monitor SSL certificate expiry across all imaging platforms, pathology reporting systems, surgical planning systems, oncology platforms, genetics systems, and patient surveillance portals. Certificate errors disrupt multimodal imaging access, molecular pathology reporting, systemic therapy administration, and recurrence surveillance workflows.
HIPAA and Genetic Data Privacy Considerations
Desmoplastic fibroma of bone technology platforms handle PHI including multimodal diagnostic imaging (plain films, MRI, CT), biopsy and operative pathology reports with CTNNB1 molecular test results, APC germline mutation results (with high-penetrance colorectal cancer risk implications and familial cascade testing requirements constituting genetic information protected under GINA and state genetic privacy laws), reconstructive surgical operative records, radiation treatment plans, systemic therapy records, and long-term post-resection surveillance imaging. HIPAA Security Rule requirements for PHI availability and integrity apply across all platforms, with APC germline mutation results requiring particularly rigorous access controls given their insurance discrimination implications and cascade family testing requirements.
For platforms supporting long-term post-resection surveillance — where MRI availability over a 5–10 year horizon determines whether local recurrence is detected at a stage amenable to re-resection vs. bulky unresectable disease — availability monitoring provides operational documentation relevant to HIPAA Security Rule administrative safeguard compliance and to the longitudinal surveillance commitments of bone tumor programs.
Alerting Strategy for Desmoplastic Fibroma of Bone Tech Platforms
Immediate alerting during imaging characterization and surgical planning: MRI and CT platforms during preoperative intraosseous extent delineation, surgical margin planning, and virtual surgical planning — these cannot fail when the surgical team is defining resection levels and reconstruction design.
Immediate alerting during pathologic diagnosis: Beta-catenin IHC and CTNNB1 molecular testing platforms cannot fail during the molecular confirmation that distinguishes intraosseous desmoid fibromatosis from low-grade bone sarcomas at the tumor board.
Immediate alerting during surgical care: Operative and perioperative platforms during mandibular, long-bone, or pelvic resection and reconstruction sessions.
Immediate alerting during systemic therapy administration: Nirogacestat, sorafenib, or imatinib prescribing and toxicity monitoring platforms cannot fail during targeted agent administration for unresectable or recurrent disease.
Immediate business-hours alert: Radiation treatment planning, tumor board, APC genetics consultation, gastroenterology coordination platforms.
Sustained-failure alert (10–15 minutes): Post-resection MRI surveillance platforms, recurrence documentation, family communication portals, genetic cascade testing coordination.
30-day advance warning: SSL certificates across all domains.
Vigilmon's multi-region monitoring confirms desmoplastic fibroma of bone platform availability from the geographies where orthopedic oncology programs with complex bone reconstruction capability, mandibular resection and free flap reconstruction expertise, molecular bone tumor pathology, and hereditary cancer genetics programs concentrate.
Status Page for Desmoplastic Fibroma of Bone Care Team Communication
A real-time status page gives orthopedic oncologists planning wide femoral resection, oral and maxillofacial surgeons designing virtual mandibulectomy reconstruction, musculoskeletal radiologists reading preoperative MRI, molecular pathologists reporting CTNNB1 sequencing results, radiation oncologists planning unresectable pelvic treatment, medical oncologists administering nirogacestat, and hereditary cancer geneticists coordinating APC cascade testing immediate platform visibility without requiring inbound IT support contact.
Include the status page URL in orthopedic oncology imaging downtime procedures, bone tumor board contingency workflows, systemic therapy emergency protocols, and post-resection surveillance downtime procedures.
Vigilmon Setup for Desmoplastic Fibroma of Bone Tech Platforms
A practical starting configuration:
| Monitor | Check Interval | Alert Channel | |---------|----------------|---------------| | Authentication | 1 min | Slack + PagerDuty (24/7) | | MRI platform (medullary extent, soft tissue, surgical planning) | 1 min | Slack + PagerDuty (clinical hours) | | CT platform (cortical detail, matrix, CT-guided biopsy) | 1 min | Slack + PagerDuty (clinical hours) | | Plain radiography | 1 min | Slack + PagerDuty (clinical hours) | | Pathology / IHC (beta-catenin, vimentin, SMA) | 1 min | Slack + PagerDuty (business hours) | | CTNNB1 / APC molecular sequencing | 1 min | Slack + PagerDuty (business hours) | | Virtual surgical planning / 3D reconstruction | 1 min | Slack + PagerDuty (clinical hours) | | Operative / perioperative records | 1 min | Slack + PagerDuty (clinical hours) | | Systemic therapy (nirogacestat, sorafenib, imatinib) | 1 min | Slack + PagerDuty (treatment hours) | | Radiation treatment planning | 1 min | Slack + PagerDuty (business hours) | | Tumor board / multidisciplinary coordination | 1 min | Slack + PagerDuty (board hours) | | APC genetics / Gardner syndrome coordination | 2 min | Slack (business hours) | | Post-resection MRI surveillance | 2 min | Slack (business hours) | | Family / patient portal | 2 min | Slack (business hours) | | SSL: all domains | Daily | Email (30-day warning) |
Getting started:
- Create a free account at vigilmon.online
- Add authentication endpoints at 1-minute intervals with 24/7 alerting
- Configure MRI platforms for medullary extent characterization and surgical margin planning with immediate clinical-hours alerting
- Add CT platforms for cortical detail and CT-guided biopsy planning with immediate clinical-hours alerting
- Configure pathology IHC platforms (beta-catenin, vimentin, SMA) with immediate business-hours alerting
- Add CTNNB1 and APC molecular sequencing platforms with immediate business-hours alerting
- Configure virtual surgical planning and 3D reconstruction platforms with immediate clinical-hours alerting
- Add operative and perioperative record platforms with immediate clinical-hours alerting
- Configure systemic therapy platforms (nirogacestat, sorafenib, imatinib) with immediate alerting during treatment sessions
- Add radiation treatment planning platforms with immediate business-hours alerting
- Configure tumor board and multidisciplinary coordination platforms with immediate alerting during board sessions
- Add APC genetics and Gardner syndrome coordination platforms with sustained-failure alerting
- Configure post-resection MRI surveillance platforms with sustained-failure alerting
- Add patient and family communication portals with sustained-failure alerting
- Enable SSL certificate monitoring across all imaging, pathology, surgical, oncology, genetics, and surveillance domains
- Add the status page URL to orthopedic oncology imaging downtime procedures, bone tumor board contingency workflows, and surveillance downtime procedures
Conclusion
Desmoplastic fibroma of bone technology platforms are embedded in clinical decisions where imaging platform availability during MRI assessment of an aggressive lytic femoral lesion in a 19-year-old — when the musculoskeletal radiologist must delineate the medullary intraosseous extent from distal to proximal in centimeters (the measurement that determines the proximal resection level), characterize the integrity of the anterior and posterior femoral cortex (determining whether cortical breakthrough has created a soft tissue component that changes the surgical approach), and assess proximity of the posterior cortex to the sciatic nerve (a proximity that, if present, requires the surgeon to plan for posterior soft tissue margin sacrifice and potential nerve monitoring) — cannot be disrupted by MRI platform failures at the surgical planning moment when the orthopedic oncologist, plastic surgeon, and prosthetics engineer are waiting for the parametric measurements that will drive the intercalary prosthesis dimensions and fixation design; where pathology platform availability during nuclear beta-catenin IHC reporting on core biopsy from a 24-year-old with a lytic mandibular lesion — when the oral and maxillofacial surgeon and the tumor board must determine whether the lesion is intraosseous desmoid fibromatosis (treatable with mandibular resection and free fibula flap reconstruction), low-grade osteosarcoma (requiring resection plus adjuvant therapy), or another entity — cannot be interrupted by LIMS platform failures that delay the beta-catenin nuclear staining result whose positivity confirms the molecular identity of the intraosseous desmoid-type fibromatosis and directs the team away from osteosarcoma chemotherapy protocols toward the surgical-first treatment paradigm; and where post-resection MRI surveillance platform availability at the 18-month post-resection surveillance visit for a 26-year-old who underwent wide pelvic resection for iliac desmoplastic fibroma — when the follow-up MRI must confirm the absence of T2 hyperintense fibrous tissue at the iliac resection margin zone, the primary radiologic evidence that local recurrence has not developed — cannot be disrupted by imaging platform failures that delay the surveillance MRI on which early recurrence detection (and the opportunity for re-resection at a salvageable stage) depends in a locally aggressive bone tumor where margin adequacy is the primary determinant of long-term local control. An imaging MRI platform unavailable when femoral medullary extent measurement drives intercalary prosthesis design, a pathology platform interrupted when nuclear beta-catenin IHC separates intraosseous desmoid fibromatosis from osteosarcoma at the tumor board, a surveillance platform unavailable when post-resection MRI is the only early warning mechanism for local recurrence in a pelvic bone tumor — these are not IT incidents. They are clinical disruptions in the management of a rare, locally aggressive intraosseous fibrous tumor whose diagnostic molecular precision, complex reconstructive surgical planning, and multi-year recurrence surveillance all depend on imaging, molecular pathology, and follow-up documentation platforms working without interruption across a long management timeline.
Uptime monitoring gives desmoplastic fibroma of bone tech teams the detection capability to identify failures within seconds, trigger immediate clinical downtime procedures, and demonstrate to orthopedic oncology programs, oral and maxillofacial surgical centers, molecular bone tumor pathology laboratories, radiation oncology services, medical oncology programs, hereditary cancer genetics services, and compliance auditors that platform operational reliability matches the imaging precision requirements, molecular diagnostic obligations, surgical reconstruction complexity, systemic therapy administration safety requirements, and long-term recurrence surveillance commitments of modern desmoplastic fibroma of bone management.
Start monitoring your desmoplastic fibroma of bone care tech platform for free at vigilmon.online — HTTP/HTTPS monitoring, multi-region consensus alerting, SSL certificate monitoring, automatic status page, Slack and webhook alerts. No agent required. No credit card.
Tags: #monitoring #desmoplasticfibroma #bone #intraosseous #desmoid #fibromatosis #betacatenin #CTNNB1 #APC #Gardnersyndrome #orthopediconcology #mandible #femur #pelvis #widereseciton #reconstruction #freefibula #nirogacestat #sorafenib #imatinib #HIPAA #cancertech #healthtech #digitalhealth #uptime #sre